Literature DB >> 31919780

Transjugular intrahepatic portosystemic shunt (TIPS): current indications and strategies to improve the outcomes.

Francesco Vizzutti1, Filippo Schepis2, Umberto Arena1, Fabrizio Fanelli3, Stefano Gitto1, Silvia Aspite1, Laura Turco2, Gabriele Dragoni1, Giacomo Laffi1, Fabio Marra4,5.   

Abstract

Transjugular intrahepatic portosystemic shunt (TIPS) represents a very effective treatment of complications of portal hypertension. Established indications to TIPS in cirrhotic patients include portal hypertensive bleeding and refractory ascites. Over the years additional indications have been proposed, such as the treatment of vascular disease of the liver, hepatic hydrothorax, hepatorenal syndrome and bleeding from ectopic varices. Indications under evaluation include treatment of portal hypertension prior to major abdominal surgery and treatment of portal vein thrombosis. In spite of these advances, there are still uncertainties regarding the appropriate workup for patients to be scheduled for TIPS. Moreover, prevention and management of post-TIPS complications including hepatic encephalopathy and heart failure are still suboptimal. These issues are particularly relevant considering aging in TIPS candidates in Western countries. Correct selection of patients is mandatory to prevent complications which may eventually frustrate the good hemodynamic results and worsen the patient's quality of life or even life expectancy. The possible role of small diameter TIPS to prevent post-procedural complications is discussed.

Entities:  

Keywords:  Ascites; Heart failure; Hepatic encephalopathy; Variceal bleeding

Mesh:

Year:  2020        PMID: 31919780     DOI: 10.1007/s11739-019-02252-8

Source DB:  PubMed          Journal:  Intern Emerg Med        ISSN: 1828-0447            Impact factor:   3.397


  79 in total

1.  Modifications of cardiac function in cirrhotic patients treated with transjugular intrahepatic portosystemic shunt (TIPS).

Authors:  Manuela Merli; Valentina Valeriano; Stefania Funaro; Adolfo Francesco Attili; Andrea Masini; Cesare Efrati; Castro Stefano De; Oliviero Riggio
Journal:  Am J Gastroenterol       Date:  2002-01       Impact factor: 10.864

2.  Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis.

Authors:  P Ginès; L Titó; V Arroyo; R Planas; J Panés; J Viver; M Torres; P Humbert; A Rimola; J Llach
Journal:  Gastroenterology       Date:  1988-06       Impact factor: 22.682

Review 3.  Hyponatremia in cirrhosis: from pathogenesis to treatment.

Authors:  P Ginés; T Berl; M Bernardi; D G Bichet; G Hamon; W Jiménez; J F Liard; P Y Martin; R W Schrier
Journal:  Hepatology       Date:  1998-09       Impact factor: 17.425

4.  Transjugular intrahepatic portosystemic shunt-related complications and practical solutions.

Authors:  Renato Ripamonti; Hector Ferral; Marc Alonzo; Nilesh H Patel
Journal:  Semin Intervent Radiol       Date:  2006-06       Impact factor: 1.513

Review 5.  Management of varices and variceal hemorrhage in cirrhosis.

Authors:  Guadalupe Garcia-Tsao; Jaime Bosch
Journal:  N Engl J Med       Date:  2010-03-04       Impact factor: 91.245

Review 6.  Cirrhotic cardiomyopathy in the pre- and post-liver transplantation phase.

Authors:  Enrico Maria Zardi; Domenico Maria Zardi; Diana Chin; Chiara Sonnino; Aldo Dobrina; Antonio Abbate
Journal:  J Cardiol       Date:  2015-06-11       Impact factor: 3.159

7.  Covered vs. uncovered stents for transjugular intrahepatic portosystemic shunt: a randomized controlled trial.

Authors:  Jean Marc Perarnau; Amélie Le Gouge; Charlotte Nicolas; Louis d'Alteroche; Patrick Borentain; Faouzi Saliba; Anne Minello; Rodolphe Anty; Carine Chagneau-Derrode; Pierre Henri Bernard; Armand Abergel; Isabelle Ollivier-Hourmand; Jérome Gournay; Jean Ayoub; Christophe Gaborit; Emmanuel Rusch; Bruno Giraudeau
Journal:  J Hepatol       Date:  2014-01-27       Impact factor: 25.083

8.  Pharmacological prophylaxis of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: a randomized controlled study.

Authors:  O Riggio; A Masini; C Efrati; F Nicolao; S Angeloni; Filippo M Salvatori; M Bezzi; Adolfo F Attili; M Merli
Journal:  J Hepatol       Date:  2005-05       Impact factor: 25.083

Review 9.  New insights into cirrhotic cardiomyopathy.

Authors:  Søren Møller; Jens D Hove; Ulrik Dixen; Flemming Bendtsen
Journal:  Int J Cardiol       Date:  2012-10-04       Impact factor: 4.164

10.  Type-2 hepatorenal syndrome and refractory ascites: role of transjugular intrahepatic portosystemic stent-shunt in eighteen patients with advanced cirrhosis awaiting orthotopic liver transplantation.

Authors:  Gianni Testino; Carlo Ferro; Alessandro Sumberaz; Piergiorgio Messa; Nicola Morelli; Barbara Guadagni; Giorgio Ardizzone; Umberto Valente
Journal:  Hepatogastroenterology       Date:  2003 Nov-Dec
View more
  4 in total

1.  External Validation of the FIPS Score for Post-TIPS Mortality in a National Veterans Affairs Cohort.

Authors:  Sara E Chapin; David S Goldberg; David E Kaplan; Nadim Mahmud
Journal:  Dig Dis Sci       Date:  2021-11-19       Impact factor: 3.487

Review 2.  Transjugular Intrahepatic Portosystemic Shunt Placement for Portal Hypertension: Meta-Analysis of Safety and Efficacy of 8 mm vs. 10 mm Stents.

Authors:  Jiangtao Liu; Eric Paul Wehrenberg-Klee; Emily D Bethea; Raul N Uppot; Kei Yamada; Suvranu Ganguli
Journal:  Gastroenterol Res Pract       Date:  2020-10-17       Impact factor: 2.260

3.  Prediction of Patient Survival with Psoas Muscle Density Following Transjugular Intrahepatic Portosystemic Shunts: A Retrospective Cohort Study.

Authors:  Biyu Zhang; Weimin Cai; Feng Gao; Xinran Lin; Ting Qian; Kaier Gu; Bingxin Song; Tanzhou Chen
Journal:  Med Sci Monit       Date:  2022-01-15

4.  Hemodynamic Evaluation of the Right Heart-Pulmonary Circulation Unit in Patients Candidate to Transjugular Intrahepatic Portosystemic Shunt.

Authors:  Giulia Manguso; Anthony Vignone; Manuela Merli; Cristiano Miotti; Annalisa Caputo; Carmine Dario Vizza; Roberto Badagliacca
Journal:  J Clin Med       Date:  2022-01-17       Impact factor: 4.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.